A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

NCT06113744 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

164

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2 Infection

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: COVID-19 Vaccine (Vero Cell) ,Inactivated
BIOLOGICAL: COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg
BIOLOGICAL: COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg
BIOLOGICAL: COVID-19 mRNA Vaccine (ZSVG-02-O) 60 μg

Sponsor

CNBG-Virogin Biotech (Shanghai) Ltd.

Collaborators

[object Object]